INBRAIN Partners with Microsoft to Develop AI-Driven Brain-Computer Interface Therapies
Spain-based INBRAIN Neuroelectronics has announced a collaboration with Microsoft to apply advanced artificial intelligence to its next-generation brain-computer interface (BCI) therapeutics. The partnership aims to harness Microsoft’s Azure AI and data infrastructure to enhance INBRAIN’s graphene-based neural platform, enabling real-time, adaptive interaction with individual patient brain signals.
The collaboration focuses on developing “agentic AI” — autonomous AI systems capable of making real-time decisions based on continuous neural data. This approach could redefine how neurological disorders such as Parkinson’s disease, epilepsy, and psychiatric or memory conditions are monitored and treated. By learning directly from neural feedback, the system could deliver highly personalized, closed-loop therapies tailored to each patient’s brain activity.
“Our vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and AI,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “By collaborating with Microsoft, we’re combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems. This partnership brings us closer to a future where brain-computer interfaces don’t just decode or modulate, but truly understand and respond to the nervous system in real time.”
Clare Barclay, President of Enterprise and Industry, EMEA at Microsoft, described the collaboration as a milestone in the evolution of AI. “INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide,” she said.
INBRAIN’s neural technology is built on graphene, a highly conductive and biocompatible material that enables precise neural decoding and stimulation. By combining this with Microsoft’s AI capabilities, the companies aim to create a new class of brain-computer interface therapeutics that can autonomously analyze and modulate neural circuits. The partnership also reflects a shared commitment to responsible innovation, data security, and patient privacy in advancing neurotechnology for clinical use.
